Reading this on a mobile device? Try our optimized mobile version here:

October 26, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Bayer, Qiagen team up to develop companion diagnostics
    Qiagen and Bayer HealthCare agreed to jointly develop companion diagnostic tests for the latter's drugs, starting with treatments for solid tumors. The assays will run on Qiagen's QIAsymphony automated instruments. The partners will also work together on technologies to identify patients who could be helped by exploratory or translational treatments. The deal sets the stage for the development of diagnostics outside oncology as well, according to a Qiagen executive. GenomeWeb Daily News (free registration) (10/25) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Domain partners with Ono to develop small molecule drugs
    Domain Therapeutics and Ono Pharmaceutical agreed to use the former's DTect-All G-protein-coupled receptor drug discovery platform to identify small molecule therapeutics. Ono will get exclusive rights to develop and market drugs arising from the collaboration. The deal entitles Domain to an upfront payment and research funding, plus milestone fees and sales royalties. Genetic Engineering & Biotechnology News (10/23) LinkedInFacebookTwitterEmail this Story
  • Rapid Pathogen offers tool for rapid pink eye diagnosis
    Rapid Pathogen Screening has developed an assay that uses technology designed for explosives detection to quickly diagnose pink eye, a condition commonly linked to adenovirus. The test, which already has been cleared in Europe and the U.S., takes about 10 minutes to detect the presence of adenovirus in tear samples collected during a clinical visit. (10/24) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • ViaCyte, Bluebird Bio receive funding from CIRM
    The California Institute for Regenerative Medicine is giving out grants totaling almost $20 million for developers working on treatments for type 1 diabetes and beta-thalassemia. ViaCyte will receive $10.1 million for clinical trials of a living artificial pancreas device called Pro-Islet that contains encapsulated pancreatic cells to supply insulin. Bluebird Bio will receive $9.3 million for the development of a treatment for beta-thalassemia. North County Times (Temecula, Calif.) (10/25) LinkedInFacebookTwitterEmail this Story
  • Human and animal cell-based systems provider raises $4M in financing
    HemoShear, which supplies biotech and drug firms with human and animal cell-based systems that replicate organs and diseases for use in the development of treatments, raised $4 million in a Series C financing round. The Charlottesville, Va.-based firm will use the proceeds to relocate to a bigger laboratory next year, and increase its science and business workforce. "Our customer base and revenues are growing rapidly," CEO Jim Powers said. (10/25) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • Support for Proposition 37 plunged last month, poll finds
    Voter support for California's Proposition 37 biotech labeling law has dropped to a virtual tie during the last month, according to a USC Dornsife/Los Angeles Times poll. The telephone survey, conducted from Oct. 15 to 21, found that 42% of voters opposed the initiative, 44% supported it and 14% were undecided. A previous poll, carried out from Sept. 17 to 23, had 25% of voters opposing the measure, 61% in favor and 14% undecided. Los Angeles Times (tiered subscription model) (10/25), Reuters (10/25) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Calif. company eyes $1.50-per-gallon gasoline from biomass
    California-based biofuels developer Cool Planet Energy Systems is planning to develop 30 small production facilities in the next three years to produce biomass-based gasoline for about $1.50 per gallon, said President and CEO Howard Janzen. Instead of larger plants that can take years to get up and running, the company wants smaller plants that can be put together using shipper-container-sized components, Janzen said. The company has received orders for $500 million worth of the gasoline, so there's "a home for this product already," he said. Bloomberg Businessweek (10/24) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Be a lion at home and a fox abroad."
--Persian proverb

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information